Abstract
Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.
This is a preview of subscription content, log in via an institution to check access.
References
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455
Birkmayer W, Mentasti M (1967) Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes). Archiv fur Psychiatrie und Nervenkrankheiten 210(1):29–35
Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti akinetic effect after l-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 36(3–4):303–326
Chen JJ, Swope DM, Dashtipour K (2007) Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 29(9):1825–1849. doi:10.1016/j.clinthera.2007.09.021
Collins GG, Youdim MB (1970) Multiple forms of human brain monoamine oxidase: substrate specificities. Biochem J 117(2):43P
Deftereos SN, Dodou E, Andronis C, Persidis A (2012) From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. Expert Rev Clin Pharmacol 5(4):413–425. doi:10.1586/ecp.12.29
Fahn S, McCall-Perez F, Hammon J, Viejo A, Telang F, Logan J, Wang GJ, Fowler J (2011) The effect of high dose orally disintegrated tablet selegiline, a selective monoaminoxidase B inhibitor, on monoaminoxidase A, and compared to EMSAM (transdermal formulation of selegiline). Neurology 1(Suppl 4):275
Green AR, Mitchell BD, Tordoff AF, Youdim MB (1977) Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 60(3):343–349
Jenner P, Langston JW (2011) Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord: Off J Mov Disord Soc 26(13):2316–2323. doi:10.1002/mds.23926
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17(7):1285–1297
Magyar K (2011) The pharmacology of selegiline. Int Rev Neurobiol 100:65–84. doi:10.1016/B978-0-12-386467-3.00004-2
Mahmood I (1997) Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 33(2):91–102
Mahmood I, Marinac JS, Willsie S, Mason WD (1995) Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm Drug Dispos 16(7):535–545
Mousseau DD, Baker GB (2012) Recent developments in the regulation of monoamine oxidase form and function: is the current model restricting our understanding of the breadth of contribution of monoamine oxidase to brain [dys]function? Curr Top Med Chem 12(20):2163–2176
Naoi M, Maruyama W, Inaba-Hasegawa K (2012) Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Curr Top Med Chem 12(20):2177–2188
Napolitano A, Cesura AM, Da Prada M (1995) The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. J Neural Transm Suppl 45:35–45
Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11(15):2033–2043
Riederer P, Gerlach M, Muller T, Reichmann H (2007) Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat disord 13(8):466–479. doi:10.1016/j.parkreldis.2007.06.015
Saura J, Kettler R, Da Prada M, Richards JG (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci: Off J Soc Neurosci 12(5):1977–1999
Acknowledgments
We would like to thank the patients and Gabi Öhm, Marion Marg, Hartmut Rothe, Matthias Küchler, Claudia Kraitzizek, Sven Lütge, Thomas Haas.
Conflict of interest
The authors declare neither competing financial interests regarding this research project nor conflicts of interest with respect to the content of the article.
Author information
Authors and Affiliations
Corresponding author
Additional information
J. Bartl and T. Müller contributed equally. M. Gerlach and P. Riederer contributed equally.
Rights and permissions
About this article
Cite this article
Bartl, J., Müller, T., Grünblatt, E. et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 121, 379–383 (2014). https://doi.org/10.1007/s00702-013-1120-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-013-1120-z